A CD4+ cell-restricted blockade of TGF-ß signaling in mice expressing a dominant negative version of the receptor resulted in eradication of TGF-ß expressing lymphoma or metastatic B16F10 melanoma (70) and has established a firm link between TGF-ß and tumor immune tolerance. This evidence concerns the gene CD4 and neoplasm.